SacredBod's longer take on Lentinan — context the structured blocks above don't capture.
Lentinan is a purified beta-(1,3)-glucan with beta-(1,6) branches isolated from shiitake mushrooms (Lentinula edodes). It is approved as a biological response modifier (BRM) for gastric cancer in Japan, where it is administered intravenously alongside chemotherapy. Oral supplements contain the same compound but at much lower, unstandardized doses.
Lentinan activates dendritic cells via TLR2/TLR4, stimulates IL-12 and IFN-γ production, and enhances NK cell cytotoxicity. It may also reduce regulatory T-cell suppression of Th1 responses. In Japan, IV lentinan has been shown to prolong survival in advanced gastric cancer when combined with chemotherapy. Oral absorption of intact beta-glucans is debated.
Who benefits most
Adults seeking immune support during or after conventional cancer therapy, or those wanting concentrated shiitake beta-glucan supplementation.
Dosage and form
500 mg is the typical effective range. Forms matter: choose standardised extracts or highly bioavailable delivery formats (see the Forms tab). Take as directed.
Side effects and cautions
Generally well-tolerated orally. Injectable use is medical-supervised. Avoid if you: Not a replacement for chemotherapy or radiation. Oral bioavailability is uncertain—do not expect IV-equivalent effects from capsules. Those with autoimmune conditions should avoid due to immunostimulatory effects..
The evidence
Human clinical trials and mechanistic research support the use of Lentinan for its primary indication. See the Research tab for full citations and study summaries.